Trial Profile
A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Ribaxamase (Primary) ; Ceftriaxone; Macrolides
- Indications Clostridium difficile infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Synthetic Biologics; Theriva Biologics
- 22 Feb 2018 According to a Synthetic Biologics media release, the company presented additional supportive results regarding several exploratory endpoints from this trial in 4Q 2017.
- 01 Nov 2017 According to a Synthetic Biologics media release, the company expects to share additional results regarding several exploratory endpoints in the fourth quarter of 2017.
- 08 Oct 2017 Results presented at the IDWeek 2017